David M Lowe

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

J. A. Guerra-Assunção, K. Hood, B. Jani, 2024, Nature communications.

Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.

Sunando Roy, J. Pang, A. Kreins, 2024, Clinical immunology.